Arthur F. Ryan, serving as a director for Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), finalized a stock sale on July 2, 2026. The transaction involved the disposal of 200 shares, generating a total proceeds amount of $130,030. The execution of this sale occurred within a specific price band, with individual shares trading between $650.10 and $650.19. The aggregate transaction utilized a volume-weighted average price of $650.15.
This disposition was facilitated through a pre-arranged Rule 10b5-1 trading plan. The framework for this specific trading arrangement was adopted on October 31, 2025. Following the completion of this transaction, Mr. Ryan's direct ownership position in Regeneron common stock stands at 17,303 shares.
Market data indicates that Regeneron stock has appreciated since the date of the transaction. The share price has advanced to $676.22, representing an increase from the $650.15 price point at which the sale was executed. Independent analysis from InvestingPro suggests that Regeneron may be trading at a discount relative to its fundamentals, citing a strong financial health score for the company. InvestingPro provides detailed research reports on over 1,400 US equities, aiming to convert complex financial data into actionable insights for market participants.
Regeneron Pharmaceuticals has recently been the subject of significant corporate developments. The company disclosed that the European Medicines Agency has accepted its Marketing Authorization Application for Otarmeni. This gene therapy is designed to address biallelic OTOF variant-associated hearing loss. The application is currently undergoing Accelerated Assessment procedures. If regulatory approval is granted, Otarmeni would become the inaugural gene therapy for this specific condition within the European Union.
Additionally, Regeneron has broadened its strategic collaboration with CytomX Therapeutics. This expanded partnership has resulted in a $37 million payment from Regeneron to CytomX for two additional development programs. The collaboration integrates CytomX's proprietary PRObody platform with Regeneron's Veloci-Bi bispecific antibody development platform.
In the clinical development sphere, Regeneron is scheduled to present data at major upcoming meetings focused on diabetes and endocrinology. These include the American Diabetes Association Scientific Sessions and the Endocrine Society Annual Meeting. The presentations will feature research on muscle biology and body composition within the context of metabolic disease. This data includes findings from the Phase 2 COURAGE trial.
Regarding market sentiment, Cantor Fitzgerald has adjusted its price target for Regeneron shares downward from $785 to $750. Despite this adjustment, the firm has maintained an Overweight rating on the stock. The revision in the price target reflects concerns regarding the performance of Eylea HD/SD and Dupixent against consensus estimates.
Regeneron also convened its 2026 Annual Meeting of Shareholders. During this meeting, several key proposals were approved, including the election of five Class II directors.
Market tracking shows Regeneron stock closing at $676.22, reflecting a gain of $26.41 or 4.06% during regular trading hours. After-hours trading saw minimal movement, with the price holding at $676.23. The stock chart data spans from 14:00 to 19:00, with price levels ranging from 655 to 675.
InvestingPro offers risk management tools for traders, including Vision AI, which analyzes charts to provide entry, stop-loss, and profit target recommendations. A promotional offer for InvestingPro was noted at a 60% discount.